Ankyra is a technology company.
Ankyra has raised $45.0M across 1 funding round.
Ankyra has raised $45.0M in total across 1 funding round.
Ankyra has raised $45.0M in total across 1 funding round.
Ankyra's investors include Kevin Hartz, Alumni Ventures, Atomico, Borealis Ventures, Krishna Yeshwant, Mithril Capital Management, Polaris Partners, RA Capital, Julia Hartz, Tom Blomfield.
Ankyra Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, developing anchored-drug conjugate technologies to expand the therapeutic window of immunotherapies for cancer and other serious diseases.[1][2][5] Its core platform creates stable drug depots via local administration, enabling prolonged immune activation with reduced systemic toxicity, and its lead candidate, ANK-101 (an IL-12 anchored-drug conjugate), is in Phase 1 trials for advanced solid tumors, with recent expansion into non-small cell lung cancer (NSCLC) via a Johnson & Johnson collaboration.[2][5] The company serves patients with solid tumors by addressing limitations in existing immunotherapies, such as dose-limiting toxicities, through tumor-retaining molecules bound to aluminum hydroxide, showing strong preclinical efficacy with single-dose activity.[1][5]
Ankyra Therapeutics emerged as a biotech focused on innovative immunotherapy delivery, though specific founding year and founders are not detailed in available sources; its team collectively has experience bringing seven drugs to global market approval, emphasizing practical execution.[3][5] Key leadership includes CEO Howard L. Kaufman, MD, who highlighted strategic hires like the recent Chief Scientific Officer Sailaja Battula, PhD (with over a decade in immuno-oncology from roles at Immuneering and Bicycle Therapeutics), alongside executives such as CFO Stephen Gorgol, CMO Joseph Elassal, CSO Robert Tighe, and Chief Process Officer Greg Zarbis-Papastoitsis.[1][4] Pivotal early momentum includes advancing ANK-101 to Phase 1 trials after robust preclinical results and securing an expanded collaboration with Johnson & Johnson in early 2025 to test in NSCLC.[2][5]
Ankyra rides the immunotherapy expansion trend in oncology, targeting unmet needs in solid tumors where systemic toxicities limit drugs like IL-12, amid rising demand for localized, sustained-release therapies.[1][5] Timing aligns with advances in drug conjugates and bispecifics, bolstered by market forces like NSCLC prevalence (most common lung cancer) and big pharma interest, as seen in its Johnson & Johnson deal.[2] It influences the ecosystem by pioneering tumor-anchored platforms, potentially enabling broader immunotherapy adoption and reducing treatment burdens.[5]
Ankyra's near-term focus will likely center on ANK-101 Phase 1 data readouts, pipeline expansion under new CSO leadership, and deepening pharma collaborations to accelerate toward approvals.[1][2] Trends like precision oncology and next-gen conjugates will shape its path, with success hinging on clinical safety-efficacy balance in NSCLC and beyond. Its influence could grow by validating anchored tech as a standard for safer immunotherapies, transforming how biotech tackles tumor-localized treatments—building on its promise to expand immunotherapy's therapeutic window.[5]
Ankyra has raised $45.0M across 1 funding round. Most recently, it raised $45.0M Series B in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $45.0M Series B | Kevin Hartz, Alumni Ventures, Atomico, Borealis Ventures, Krishna Yeshwant, Mithril Capital Management, Polaris Partners, RA Capital, Julia Hartz, Tom Blomfield |